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Abstract The heterocyclic organic compound ebselen (2-
phenyl-1,2-benizsoselenazol-3(2H)-one) is a glutathione
peroxidase mimick with protective properties against oxi-
dative injury. Ebselen also has anti-inflammatory activity,
including attenuation of tumor necrosis factor release and
increase of interleukin-10, as shown in vivo, in inflam-
matory and ischemia-reperfusion injuries, including those
of the lung. This study was designed to assess its effect on
severe ischemia-reperfusion injury in a model of left-sided
rat lung isotransplantation. Orthotopic single left-sided
lung allotransplantation (Wistar to Wistar) was performed
in female rats after a total ischemic time of 18 h. In nine
recipients given 500 mg/kg oral ebselen 1 h before trans-
plantation, graft PaO2/FiO2 was improved 24 h after
transplantation, as evidenced with a mean (standard devi-
ation) PaO2 of 139 (61) mmHg vs. eight controls with 65
(33) mmHg (p = 0.009). Bronchoalveolar PMN count was
reduced to approximately 50% in the ebselen group com-
pared with controls, whereas no difference in the tumor
necrosis factor content was found. We conclude that the
improvement of lung function in ebselen-treated trans-
planted rats is mainly the result of the anti-inflammatory
activity of the drug during reperfusion.
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Introduction
Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) is a
selenium-containing organic compound that has protective
properties against oxidative injury by mimicking the activity
of the selenoenzyme glutathione peroxidase, i.e., by cata-
lyzing the reduction of hydrogen peroxide or lipid
hydroperoxides to the corresponding alcohols and water via
oxidation of reduced glutathione [1, 2]. Furthermore, ebse-
len inhibitis 5-lipoxygenase, inducible NO synthase, and
NADPH-cytochrome P-450 reductase [3–5]. The inactiva-
tion of leukotriene B4 by isomerization to its inactive 6-trans
form by ebselen was one of the primary findings to explain
the anti-inflammatory activity of ebselen, which was later
extended to immunopharmacological in vivo actions, such
as protection of endotoxin-challenged mice or protection
against T-cell-mediated hepatic injury via attenuation of
tumor necrosis factor (TNF)-a and increase of interleukin-
10 release [6–10]. The observation that in vitro ebselen
scavenges peroxynitrite [11, 12] needs its clear significance
in vivo confirmed [13, 14]. Animal inflammatory and cere-
bral, cardiac, hepatic, and renal ischemia-reperfusion or
toxic injury models as well as protection from noise expo-
sure demonstrated its anti-inflammatory or organ-preserving
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pharmacological potential [7, 15–29]. In models of alveolar
inflammation, edema generation was virtually blocked, and
bronchoalveolar lavage TNF-a was dose-dependently
reduced [13, 30–32]. In the presence of ebselen, the sur-
factant peroxidation caused by polymorphonuclear
neutrophil granulocytes (PMN) could significantly be
reduced, as elegantly shown by in vitro models [33]. In a
clinical setting, ebselen could reduce the infarct size of
stroke patients. A study showed that patients with acute
ischemic stroke and with complete occlusion of the middle
cerebral artery had smaller infarct sizes in the ebselen-
treated group than in usual control treatments [34].
Pulmonary ischemia-reperfusion injury after transplan-
tation leads to a noncardiogenic hyperpermeability
pulmonary edema, together with a variable degree of
inflammation [35]. Lung transplantation after prolonged
graft ischemia may result in severe, highly inflammatory,
acute lung injury [36]. A powerful nonspecific immune
response occurs in both the interstitial and alveolar space,
with polymorphonuclear neutrophils, complement activa-
tion, and cytokine release, such as interleukin-8 or TNF,
and radicals are thought to play a central role in its path-
ogenesis [36–38]. This clinical background prompted us to
assess the efficacy of ebselen on severe ischemia-reperfu-
sion injury. We used a model of left-sided rat lung
allotransplantation with a prolonged period of total ische-
mia of 18 h. Outcome parameters were the graft’s gas
exchange assessed at 24 h after transplantation, as well as
surrogates of the alveolar inflammatory process that
occurred in form of a reperfusion injury.
Material and Methods
Weight-matched female Wistar rats, weighing 226 (stan-
dard deviation, 15) g, received orthotopic single left lung
allografts after a total graft ischemia of 18 h; nine recipi-
ents were treated with 500 mg/kg oral ebselen 1 h before
reimplantation compared with eight vehicle-only controls.
A cuff technique for the vessel anastomoses and a running
suture for the bronchial anastomosis were applied. The
experiments were performed according to the Helsinki
convention for the use and care of animals and were
approved by the local review boards for animal care.
Donor Procedure
Animals were anesthetized by intraperitoneally adminis-
tered pentobarbital (50 mg/kg) and heparinized (500 IU/
kg). A tracheotomy was performed, and the animals were
ventilated through a 14G catheter (Insyte, Becton Dickin-
son, Madrid, Spain) by a Unno rodent ventilator (Hugo
Sachs Harvard Apparatus, March-Hugstetten, Germany) at
a tidal volume of 8 ml/kg at 100/’, FiO2 = 1.0. After
median sternotomy, division of the inferior vena cava, and
resection of the left appendix of the heart, a small silicon
tube was inserted into the main pulmonary artery. Both
lungs were flushed with 20 ml of low potassium dextrane
(LPD) solution (Perfadex, provided by Xvivo, Go¨teborg,
Sweden) at a pressure of 20 cm H2O. The trachea was tied
in end-inspiration, the heart-lung block removed, the left
lung dissected, and 16G cuffs were placed around its pul-
monary artery and vein. The vessels were inverted and tied
onto the cuff with an 8–0 monomeric filament. The lung
was stored in LPD solution at 1.5C until implantation.
Recipient Procedure
In the treatment group, 500 mg/kg of ebselen was given by a
feeding tube in 2 ml (consisting of 10% vehicle solution for
cyclosporine A as a dissolvent, provided by Novartis, Basel,
Switzerland, and 90% NaCl 0.9%), 1 h before reimplanta-
tion, or vehicle, respectively, in the control group.
Transplantation was performed after 18 h of cold
ischemia at 1.5C. The recipient was anesthetized by
breathing 4% halothane in a glass chamber followed by
endotracheal transoral intubation with a 14G catheter
(Insyte, Becton Dickinson, Madrid, Spain). Anesthesia was
maintained with halothane 2%. A left lateral thoracotomy
was performed in the fourth intercostal space. The left
hilum was dissected. After clamping the left pulmonary
artery and vein with removable microvascular clips, the
pulmonary vein was opened, flushed with heparinized
saline solution, and the cuff was inserted and fixed with 6–
0 silk. With the same technique, the pulmonary artery was
anastomosed. The native left lung was removed and the
bronchial anastomosis performed with a running over-and-
over suture with 9–0 Monosof (Tyco Healthcare, Wollerau,
Switzerland). The lung was first reventilated and then
reperfused. A chest tube was inserted and the thoracotomy
closed. The chest tube was removed after restoration of
spontaneous breathing when the animal was extubated.
Assessment
Twenty-four hours after transplantation, the recipient ani-
mal was anesthetized by intraperitoneal pentobarbital
(50 mg/kg) and ventilated after tracheotomy with an FiO2
of 1.0 at 100 per min, a tidal volume of 8 ml/kg, and a
positive end-expiratory pressure (PEEP) of 5 cm H2O, and
performing all 2-min recruitment maneuvers through the
doubling of tidal volume by blocking the expiratory
respiratory circuit most proximal possible to the animal’s
tube immediately after the T piece that reunites inspiratory
and expiratory tubing and the Luer lock tube connection.
For functional assessment of the transplanted left lung, the
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right hilum was dissected and the right pulmonary artery
and right main bronchus were occluded with microvascular
clips. Five minutes after occlusion, a steady state was
reached and an arterial blood gas sample was drawn from
the thoracic aorta and assessed (ABL50 blood gas analyzer,
Radiometer Copenhagen). After intracardiac heparinization
with 500 U/kg, a bronchoalveolar lavage (BAL) was per-
formed in the left lung (as the right main bronchus was
clipped) with 2 ml of PBS. The microvascular clips were
then removed and the lungs were flushed with 20 ml of
saline solution through the pulmonary artery. The heart-
lung block was excised and the lungs separated: one slice
of approximately 4-mm thickness at the height between
middle and lower third of the left lung leading to the hilus
was put in 10% PBS-buffered formalin solution (Sigma),
paraffin-embedded, of which 4-lm slides were colored
with hematoxylin-eosin for histology. The remaining left
(three portions) and right (three portions) lung tissue was
stored at -70C.
BAL cell count was performed with a hemocytometer,
and a cytocentrifugation preparation was performed with
100 ll of BAL fluid in cytospin inserts (Themo Shandon,
Pittsburgh, PA, USA) in a Heraeus Minifuge RF centrifuge
(8 min, 70 g; Heraeus, Wernheim, Germany), which was
stained with May-Gru¨nwald Giemsa to perform a 300-cell
differential count. BAL fluid supernatant and serum were
obtained after centrifugation (10 min, 300 g at 4C, He-
raeus Minifuge RF) and stored at -20C until analysis. The
bronchoalveolar supernatant protein content was deter-
mined with the method of Pierce et al. according to the
manufacturer’s protocol.
Statistical Analysis
For PaO2, the mean (standard deviation), and for histo-
logical grading, the median (range) is given. Two-sided
tests were used: t tests for continuous variables if normally
distributed, and the Mann–Whitney U test for non-Gauss-
ian distributed or categorical variables were applied,
respectively. Boxplots were used, indicating median, 25th
and 75th percentile as well as 10th and 90th percentile of
distribution. The Systat software version 10.2, Systat,
Abingdon, USA) was used. p B 0.05 was considered
significant.
Results
Graft PaO2/FiO2 at 24 h after transplantation in nine
recipients treated with 500 mg/kg of oral ebselen 1 h
before reimplantation was superior with a PaO2 of 139 (61)
mmHg compared with vehicle-only controls with 65 (33)
mmHg (p = 0.009; Fig. 1).
Bronchoalveolar lavage cell counts and differentials,
their significance levels, and cytokine levels are given in
Table 1. The absolute PMN count of the ebselen and the
vehicle control group is given in Fig. 2.
Histology revealed in both study groups a grossly con-
served lung structure, engorged alveolar septa with mainly
polymorphonuclear neutrophil leukocyte (PMNs) infil-
trates, important alveolar haemorrhage, alveolar
proteinaceous material consistent with exudate, and mod-
erate to marked alveolar PMNs. Widened perivascular and
peribronchial spaces could be observed, without changes in
bronchial or bronchiolar epithelium. Histologically, there
was a marked acute neutrophil pleuritis. However, there
was no clear evidence of difference in inflammatory
changes in the two treatment groups (not shown).
Discussion
This study demonstrates in a model of severe acute lung
injury by ischemia and reperfusion that ebselen pretreat-
ment results in a clearly improved gas exchange of the
transplanted lung associated with much less increase of the
bronchoalveolar PMN count, whereas the alveolar protein
content as a rough measure of the alveolar-capillary barrier
function was not significantly decreased. Due to the com-
plexity of the model we refrained from performing further
dose-finding studies in view of the obvious results obtained
at the single dose chosen.
Fig. 1 PaO2/FiO2 of the transplanted left lung determined by blood
gas analysis 5 min after exclusion of the right-sided lung by an
arterial and a bronchial clamp. The boxplots indicate median, 25th
and 75th percentile, as well as 10th and 90th percentile of distribution
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The observed reduction of severe acute lung injury in
this clinically oriented in vivo-model is in accordance to
several previous findings on experimental lung injury. In-
tratracheally or intravenously administered Sephadex beads
trigger both a nonspecific inflammation and, due to
endogenous rat hypersensitivity to dextrane, a hypersensi-
tivity reaction which leads at 24 h to a highly cellular, i.e.,
mixed neutrophilic, but also eosinophilic and lymphocytic
alveolitis with interstitial lung edema [30, 39]. After eb-
selen pretreatment, Cotgreave et al. observed in this
Sephadex model that the development of lung edema could
be completely inhibited [30]. Belvisi et al. demonstrated
with a similar injury a dose-related inhibition of lung
edema by ebselen with an ED50 of approximately 5 mg/kg
[31]. TNF-a has been shown to be a mediator in animal
models of both acute lung injury-induced and antigen-
induced lung edema [37, 39, 40, 41]. Although Belvisi
et al. observed a reduction of bronchoalveolar lavage
supernatant TNF-a by a factor of three at doses of 10 mg/
kg or more, parallel to the pulmonary edema reduction, no
significant inhibitory effect was seen concerning broncho-
alveolar endothelin-1 [31]. Whereas in the Sephadex model
ebselen reduced the lymphocytes and eosinophil count, the
neutrophil count remained virtually unchanged in one
study [30]. This parameter was not determined in the study
of Belvisi et al. who found TNF-a reduced in the BAL [31].
However, a further Sephadex study demonstrated that the
administration of the TNF-a blocking soluble TNF type I
receptor-IgG heavy chain complex clearly reduced the
neutrophil, but not eosinophil BAL count, underlining a
critical role of TNF-a in the neutrophilic inflammation of
such injury.
In our study, where surgical or microtraumatic stress
plus ischemia/reperfusion rather than an artificial inflam-
matory challenge was used, PMN were reduced in the BAL
by a single and early ebselen pretreatment. Because we did
not find a significant difference in BAL TNF-a levels
between the studied animal groups, we can neither attribute
this attenuation of PMN infiltration to known in vitro or in
vivo TNF-a effects, nor exclude this possibility [8–10].
One possible explanation might be the late point of TNF-a
determination in BAL at 24 h after reperfusion that we
used in that study, which may be much after its peak tis-
sular release [37]. Furthermore, the lack of a significant
difference in TNF-a as well as the bronchoalveolar protein
levels may be attributed in part to a larger variation in the
transplant model: at least in the Sephadex model an
attenuation of the capillary leak by such ebselen treatment
was observed [31]. Bronchoalveolar protein content has
been assessed as a rough measure of the capillary-alveolar
function. However, although the increase in bronchoalve-
olar protein content is a good measure of an increase in
capillary-alveolar permeability in the acute phase of lung
injury, it may be misleading in a later phase when the
healing of the capillary-alveolar barrier coincides with
pulmonary edema resolution. Actually, the protein con-
centration may double in the alveolar fluid in less than 24 h
because fluid reabsorption is much faster than protein
Table 1 Bronchoalveolar
lavage fluid findings at 24 h
posttransplantation
Values are indicated as mean
(SD)
Ebselen treatment (n = 9) Vehicle control (n = 8) p
Bronchoalveolar lavage cell count 34*104 (10*104)/ml 50*104 (13*104)/ml 0.09
% of polymorphonuclear neutrophil
granulocytes (PMN)
57 (11)% 74 (5)% 0.004
Absolute PMN count 20*104 (7*104)/ml 42*104 (14*104)/ml 0.002
Absolute red blood cell count 690*104 (372*104)/ml 767*104 (410*104)/ml 0.69
Protein content 7.5 (1) g/100 ml 9.0 (1.3) g/100 ml 0.16
TNF 1 (2) pg/ml 13 (21) pg/ml 0.16
CINC-3 79 (73) 157 (241) pg/ml 0.38
IL-10 22 (20) 51 (54) pg/ml 0.19
Fig. 2 Polymorphonuclear granulocyte count of transplanted left
lung’s bronchoalveolar lavage fluid. The boxplots indicate median,
25th and 75th percentile, as well as 10th and 90th percentile of
distribution
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reabsorption. Because bronchoalveolar lavage artificially
reintroduces free fluid in the alveolus, interpretation of
alveolar protein content must be done with caution in later
points of acute lung injury.
Histological differences were not evident, which is the
case in this model even with important functional differ-
ence. One reason may be that one usually cannot assess
alveolar edema unless fixation is specifically aimed at this,
and the other is that small differences can much more
reliably be assessed when principles of unbiased stereology
are followed [42].
Whether other actions of ebselen, such as that on leu-
kotrienes, or more general signal transduction-modulating
effects or radical scavenger effects of ebselen contribute to
the improvement seen in our model, remains unanswered
[1, 2, 6]. Because reactive-oxygen species are considered
important effectors of the hypoxic pulmonary vasocon-
striction, the anti-oxidative properties of ebselen might
increase blood flow in the worst ventilated areas, therefore,
increase ventilation-perfusion mismatch and thus decrease
PaO2/FiO2 in ebselen-treated animals during assessment.
However, the magnitude of effect between ebselen-treated
and control animals was high, and this difference between
groups could only be underestimated by such a postulated,
but pathophysiologically described, effect of decreasing
hypoxic pulmonary vasoconstriction due to ebselen [43].
Conclusions
Ebselen significantly improved the transplanted rat lung
function at 24 h after transplantation. The pharmacody-
namic potency of ebselen in this model seems comparable
with a combined PAF and endothelin inhibition in a similar
setting, but less potent than complement blockade [36, 44].
Therefore, the drug may be regarded as an interesting anti-
inflammatory adjunct to other blocking strategies in pul-
monary reperfusion injury.
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